Phyteau

Phyteau is developing a new drug for the treatment of diabetes, obesity, weight loss, and related metabolic diseases such as NAFLD and NASH. The company's therapeutic approach works within the gut, triggering key cellular receptors that lead to the release of therapeutic levels of critical metabolic hormones such as GLP-1, PYY, and CCK. The action of these hormones is natural and safe, regulating blood sugar, appetite, food intake, and metabolism.The company continues to develop new solutions to help people around the world suffering from metabolic diseases.Phyteau was founded in 2017 and is headquartered in Santa Fe, New Mexico.